The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | A | Alimentary tract and metabolism | |
2 | A03 | Drugs for functional gastrointestinal disorders | |
3 | A03A | DRUGS FOR FUNCTIONAL BOWEL DISORDERS | |
4 | A03AB | Synthetic anticholinergics, quaternary ammonium compounds |
Code | Title | |
---|---|---|
A03AB01 | Benzilone | |
A03AB02 | Glycopyrronium bromide | |
A03AB03 | Oxyphenonium | |
A03AB04 | Penthienate | |
A03AB05 | Propantheline | |
A03AB06 | Otilonium bromide | |
A03AB07 | Methantheline | |
A03AB08 | Tridihexethyl | |
A03AB09 | Isopropamide | |
A03AB10 | Hexocyclium | |
A03AB11 | Poldine | |
A03AB12 | Mepenzolate | |
A03AB13 | Bevonium | |
A03AB14 | Pipenzolate | |
A03AB15 | Diphemanil | |
A03AB16 | (2-benzhydryloxyethyl)diethyl-methylammonium iodide | |
A03AB17 | Tiemonium iodide | |
A03AB18 | Prifinium bromide | |
A03AB19 | Timepidium bromide | |
A03AB21 | Fenpiverinium | |
A03AB53 | Oxyphenonium, combinations |
Active Ingredient | Description | |
---|---|---|
Fenpiverinium |
|
|
Glycopyrronium |
Glycopyrronium is an inhaled long-acting muscarinic receptor antagonist (anticholinergic) for once-daily maintenance bronchodilator treatment of COPD. Glycopyrronium works by blocking the bronchoconstrictor action of acetylcholine on airway smooth muscle cells, thereby dilating the airways. |
|
Isopropamide |
|
|
Mepenzolate |
|
|
Otilonium |
Otilonium is endowed with a marked spasmolytic action on the smooth muscle of the digestive tract. |
|
Prifinium |
Prifinium is an anticholinergic preferably acting at muscarinic receptors in the gastrointestinal tract. Prifiniumโs mechanism of action is believed to be due to its activity as an antispasmodic agent. It is used primarily in the treatment of irritable bowel syndrome. |
|
Propantheline |
Propantheline inhibits parasympathetic activity by blocking the action of the neurohormone, acetylcholine, on the neuroeffector cell. This blocking action of propantheline is instrumental in reducing gastric acid secretion and gastrointestinal motor activity. |
|
Timepidium |
|
|
Tiquizium bromide |
|
Title | Information Source | Document Type | |
---|---|---|---|
CUVPOSA Oral solution | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
FRIDIAL Oral solution | MPI, EU: SmPC | ||
PRO-BANTHINE Tablet | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ROBINUL Solution for injection | FDA, National Drug Code (US) | MPI, US: SPL/Old | |
ROBINUL Tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
RYBRILA Oral solution | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
SIALANAR Oral solution | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
SPASMOMEN Film-coated tablet | Medicines Authority (MT) | MPI, EU: SmPC |